| Name | Title | Contact Details |
|---|
John J. Morgan and David R. White founded MorganWhiteGroup, Inc. in 1987. The business started out primarily focusing on payroll deduction of supplemental insurance products, and has grown into what is today, a holding company made up of 6 wholly owned subsidiaries. The MorganWhiteGroup of companies now includes: Two sales agencies, MWG Employer Services and MWG Senior Healthcare, two third-party administrators (TPAs), MorganWhite Administrators, Inc. and MorganWhite Administrators International, a marketing agency, MWG Marketing, and a Reinsurance Intermediary, MWG Reinsurance, Inc. Our success since 1987 has been achieved by delivering insurance products to the marketplace that cannot be found anywhere else. Our company's guiding principal has been to find a market that is either under-served or not served at all and design a product to fit that market. At MorganWhiteGroup, we look forward to the challenge of solving customers’ medical, dental and vision insurance needs today, and in the future. We are committed to making the investment in technology, equipment, and personnel to provide our customers with the latest, most up to date tools available, to solve their insurance needs.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
Rehabilitation Network is a Youngstown, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
EDCO is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CalorieKing Wellness Solutions is a El Cajon, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.